Advertisement
Screener

BRIACELL THERAPEUTICS CORP. (BCTX) Amortization

2.8 / 5 stars · 68/120 Roast Me

BRIACELL THERAPEUTICS CORP. Amortization

BRIACELL THERAPEUTICS CORP. (BCTX) reported Amortization of $11.45 thousand for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.

Financial Statements › Cash Flow › Operating Activities

us-gaap:AdjustmentForAmortization · last filed 2026-06-09

  • BRIACELL THERAPEUTICS CORP. amortization for the quarter ending 2026-04-30 was $3.82K, a 0.00% change year-over-year.
  • BRIACELL THERAPEUTICS CORP. amortization for the quarter ending 2026-01-31 was $3.82K, a 0.00% change year-over-year.
  • BRIACELL THERAPEUTICS CORP. amortization for the quarter ending 2025-10-31 was $3.82K, a 0.00% change year-over-year.
  • BRIACELL THERAPEUTICS CORP. amortization for the quarter ending 2025-07-31 was $3.82K.
  • BRIACELL THERAPEUTICS CORP. amortization for fiscal 2025 was $15.27K, a 0.00% change from fiscal 2024.
  • BRIACELL THERAPEUTICS CORP. amortization for fiscal 2024 was $15.27K, a 0.00% change from fiscal 2023.
  • BRIACELL THERAPEUTICS CORP. amortization for fiscal 2023 was $15.27K, a 0.01% decline from fiscal 2022.
  • BRIACELL THERAPEUTICS CORP. amortization for fiscal 2022 was $15.27K.
Period endAmortization 3 monthAmortization 6 monthAmortization 9 monthAmortization 12 month
2026-04-30$3.82K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09
$7.63K
derived: sum of 2 quarters · filed 2026-06-09
$11.45K
10-Q · filed 2026-06-09
$15.27K
derived: sum of 4 quarters · filed 2026-06-09
2026-01-31$3.82K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10
$7.64K
10-Q · filed 2026-03-10
$11.45K
derived: sum of 3 quarters · filed 2026-03-10
$15.27K
derived: sum of 4 quarters · filed 2026-06-09
2025-10-31$3.82K
10-Q · filed 2025-12-11
$7.64K
derived: sum of 2 quarters · filed 2025-12-11
$11.45K
derived: sum of 3 quarters · filed 2026-06-09
$15.27K
derived: sum of 4 quarters · filed 2026-06-09
2025-07-31$3.82K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16
$7.63K
derived: sum of 2 quarters · filed 2026-06-09
$11.45K
derived: sum of 3 quarters · filed 2026-06-09
$15.27K
10-K · filed 2025-10-16
2025-04-30$3.82K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09
$7.63K
derived: sum of 2 quarters · filed 2026-06-09
$11.45K
10-Q · filed 2026-06-09
2025-01-31$3.82K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10
$7.64K
10-Q · filed 2026-03-10
2024-10-31$3.82K
10-Q · filed 2025-12-11
2024-07-31$15.27K
10-K · filed 2025-10-16
2023-10-31$3.82K
10-Q · filed 2024-12-16
2023-07-31$15.27K
10-K · filed 2024-10-29
2022-07-31$15.27K
10-K · filed 2023-10-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
PMGC Holdings Inc. (ELAB)United States$0.037B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
Edesa Biotech, Inc. (EDSA)Canada$0.039B
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98